Guardian Pharmacy Services, INC

Guardian Pharmacy Services, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and advisory votes on executive compensation and auditor ratification.

Guardian Pharmacy Services announced robust first-quarter 2026 financial results, exceeding prior-year performance and updating full-year guidance with increased Adjusted EBITDA.

Guardian Pharmacy Services completed a $213.9 million public offering of Class A common stock, leading to the loss of its controlled company status and a shift in corporate governance.

Guardian Pharmacy Services reiterates its 2025 financial guidance and provides a preliminary 2026 outlook, projecting adjusted EBITDA growth despite Inflation Reduction Act impacts.

Guardian Pharmacy Services reports strong third-quarter 2025 financial results, including 20% revenue growth and a significant net income turnaround, leading to raised full-year guidance.

Guardian Pharmacy Services, Inc. announced new lock-up agreements with founders, officers, and employees, restricting the sale of approximately 93% of their shares until June 30, 2026.

Guardian Pharmacy Services reports a 2.2% revenue increase in Q1 2026, driven by acquisitions, despite organic revenue decline due to IRA pricing.

Guardian Pharmacy Services, Inc. reported a significant turnaround in profitability and robust revenue growth for the third quarter and first nine months of 2025, driven by organic expansion and strategic acquisitions.

Guardian Pharmacy Services, Inc. reported significant revenue and Adjusted EBITDA growth for Q2 and H1 2025, driven by organic expansion and strategic acquisitions, despite a decline in GAAP net income due to post-IPO accounting changes.

Guardian Pharmacy Services reports a 19.6% increase in revenue for Q1 2025, driven by both acquisitions and organic growth, marking its first quarter as a public company.

Guardian Pharmacy Services reports its Q3 2024 results, which include a significant net loss due to costs associated with its recent IPO and corporate reorganization, despite revenue growth.

Guardian Pharmacy Services reports its first full year results post-IPO, highlighting revenue growth alongside increased expenses and a net loss.

Mary Sue Patchett, a Director at Guardian Pharmacy Services, Inc., reported the acquisition of 4,028 shares of Class A Common Stock on May 5, 2026.

Pharmacy Investors, LLC, a member of a 10% owner group, converted 1,413,939 shares of Guardian Pharmacy Services, Inc. Class B common stock to Class A common stock.

William E. Bindley, a Director and 10% Owner of Guardian Pharmacy Services, Inc., converted over 6 million Class B common shares into Class A common shares as part of a pre-scheduled event.

Kendall Forbes, EVP of Guardian Pharmacy Services, converted 608,570 Class B common shares to Class A common shares as part of a scheduled plan.

Cardinal Equity Fund, L.P. converted 471,057 Class B common shares of Guardian Pharmacy Services, Inc. into Class A common shares as part of a pre-scheduled automatic conversion.

David K. Morris, CFO of Guardian Pharmacy Services, Inc., converted 641,869 shares of Class B common stock into Class A common stock as part of a pre-scheduled automatic conversion.

Guardian Pharmacy Services, Inc. announced its 2026 Annual Meeting agenda, including director elections and executive compensation votes, while also disclosing its recent transition from a 'controlled company' status.

Guardian Pharmacy Services will hold its annual stockholders meeting on May 9, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as its independent auditor.

Guardian Pharmacy Services will hold its annual meeting of stockholders on May 9, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

Guardian Pharmacy Services files an S-1 registration for a secondary offering of Class A common stock, with a portion of the proceeds earmarked for a synthetic secondary transaction.

Guardian Pharmacy Services files a registration statement to increase its Class A common stock offering by 1,437,500 shares, including an underwriter option.

Guardian Pharmacy Services files an amended S-1 registration statement, updating its bylaws and providing further details on its upcoming IPO.

Guardian Pharmacy Services secures a sixth amendment to its loan agreement, waiving existing defaults and paving the way for its initial public offering.

Key shareholders of Guardian Pharmacy Services, Inc. sold 5.88 million Class A common shares, including an underwriter option, and are subject to a 180-day lock-up period.

An amended Schedule 13D filing reveals updated beneficial ownership percentages for Guardian Pharmacy Services, Inc.'s Class A common stock, incorporating future conversions of Class B shares by major holders.

A group of reporting persons, including Bindley Capital Partners I, LLC, have significantly reduced their collective beneficial ownership in Guardian Pharmacy Services, Inc. by selling over 7 million shares.

A group of founders and key investors in Guardian Pharmacy Services, Inc. have filed a Schedule 13D, disclosing their collective beneficial ownership of 46.5% of Class A common stock and outlining the automatic conversion schedule for their Class B shares.

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 6.5% of Guardian Pharmacy Services Inc.'s Class A Common Stock as of March 31, 2026.

Brown Advisory Inc. and its affiliates have disclosed a 4.54% beneficial ownership stake in Guardian Pharmacy Services, Inc.'s Class A Common Stock.

Wellington Management Group and its affiliates have filed an amended Schedule 13G, reporting a 3.1% beneficial ownership stake in Guardian Pharmacy Services, Inc. as of December 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.2% beneficial ownership stake in Guardian Pharmacy Services, Inc.'s Class A Stock.

J. Goldman & Co. and affiliates reported a 2.89% beneficial ownership stake in Guardian Pharmacy Services, Inc. common stock via an amended Schedule 13G.

Wellington Management Group LLP and its affiliates have reported a 5.0% beneficial ownership stake in Guardian Pharmacy Services, Inc. common stock.